NCT03495024View on ClinicalTrials.gov

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

PHASE4RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

April 30, 2020

Study Completion Date

June 30, 2020

Conditions
SchizophreniaSchizoaffective DisorderTobacco SmokingTardive DyskinesiaParkinsonism
Interventions
DRUG

Varenicline

Oral medication approved to facilitate smoking cessation

Trial Locations (1)

19104

RECRUITING

Corporal Michael J Crescenz VA Medical Center, Philadelphia

All Listed Sponsors
lead

Corporal Michael J. Crescenz VA Medical Center

FED